This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

XOMA To Present At Upcoming Investor Conferences

BERKELEY, Calif., Feb. 21, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that management is scheduled to present at three upcoming investor conferences. The details are as follows:

  • RBC Capital Markets Global Healthcare Conference on Tuesday, February 26, 2013 at 11:30 a.m. ET at The New York Palace Hotel
  • Cowen and Company 33 rd Annual Health Care Conference on Wednesday, March 6, 2013 at 8:40 a.m. ET at The Boston Marriott Copley Place
  • 25 th Annual ROTH Conference on Monday, March 18, 2013 at 2:00 p.m. PT at The Ritz-Carlton, Laguna Niguel

Live audio webcasts of the presentations can be accessed through the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm . Archived versions of the webcast will be available via replay for 30 days following the presentation.

About XOMA Corporation

XOMA combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations.  XOMA focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Les Laboratoires Servier (Servier) through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major effect on the treatment of diabetes. In order to retain significant value from its scientific discoveries, XOMA initiated commercial operations in January 2012 through the licensing of U.S. commercial rights to Servier's ACEON ® (perindopril erbumine) and a patent-protected portfolio of product candidates. 

The XOMA Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5960

More detailed information can be found at www.xoma.com

CONTACT: Company and Investor Contacts:
         Ashleigh Barreto
         510-204-7482
         barreto@xoma.com
         
         Juliane Snowden
         The Oratorium Group, LLC
         jsnowden@oratoriumgroup.com
         
         Media Contact:
         Canale Communications
         Carolyn Hawley
         619-849-5375
         carolyn@canalecomm.com

XOMA Corporation Logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,932.54 -137.86 -0.76%
S&P 500 2,093.05 -21.44 -1.01%
NASDAQ 4,943.1480 -73.7810 -1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs